Media headlines about Trinity Biotech (NASDAQ:TRIB) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Trinity Biotech earned a news impact score of 0.05 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.7770350709158 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Separately, Zacks Investment Research downgraded shares of Trinity Biotech from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 1st.
Trinity Biotech (TRIB) traded down $0.21 during trading on Thursday, reaching $5.42. 38,122 shares of the company traded hands, compared to its average volume of 57,328. The company has a debt-to-equity ratio of 0.90, a current ratio of 5.16 and a quick ratio of 3.77. Trinity Biotech has a 12-month low of $4.22 and a 12-month high of $7.20. The firm has a market cap of $132.22, a P/E ratio of -0.31 and a beta of 1.40.
Trinity Biotech (NASDAQ:TRIB) last issued its quarterly earnings results on Thursday, October 26th. The company reported $0.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.03. The company had revenue of $25.60 million during the quarter, compared to analysts’ expectations of $25.52 million. Trinity Biotech had a net margin of 1.74% and a return on equity of 1.67%. research analysts predict that Trinity Biotech will post 0.06 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/11/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-trinity-biotech-trib-stock-price.html.
Trinity Biotech Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.